Acquiring Company
Tvardi Therapeutics, Inc.
Acquired Company
Cara Therapeutics
HoustonStamfordHealthcareBiotechnologyHealth CareTherapeuticsDescription
Tvardi Therapeutics has completed its merger with Cara Therapeutics, creating a Nasdaq-listed company focused on STAT3 therapies for fibrosis-driven diseases. The merger is set to enhance the combined company's resources for developing important clinical treatments. Shares will begin trading under the ticker 'TVRD' on April 16, 2025. This merger marks a significant step for both companies in their drug development initiatives.
Quick answer
Tvardi Therapeutics, Inc. is acquiring Cara Therapeutics, announced April 15, 2025. Tvardi Therapeutics, Inc. is based in Houston, Texas, United States.
- How much did Tvardi Therapeutics, Inc. pay for Cara Therapeutics?
- The deal value was not disclosed.
- What does Tvardi Therapeutics, Inc. do?
- Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the..
- Where are Tvardi Therapeutics, Inc. and Cara Therapeutics based?
- Tvardi Therapeutics, Inc. is based in Houston, Texas, United States. Cara Therapeutics is based in Stamford, Connecticut, United States.
- Who are the decision-makers at Tvardi Therapeutics, Inc?
- Fundz holds 1 contact at Tvardi Therapeutics, Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie to acquire Cerevel Therapeutics for $45 per share (May 28, 2025)
- AbbVie to acquire Cerevel for $45 per share (April 15, 2025)
- AbbVie acquires Cerevel Therapeutics for $45 per share (March 31, 2025)
- OS Therapies completes acquisition of Advaxis assets from Ayala Pharmaceuticals (April 12, 2025)
- Novartis completes acquisition of Anthos Therapeutics (April 4, 2025)
- Novartis acquires Anthos Therapeutics for $3.1B, $3.1B (April 3, 2025)
Who to call at Tvardi Therapeutics, Inc., and when
When Tvardi Therapeutics, Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Tvardi Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Tvardi Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tvardi Therapeutics, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tvardi Therapeutics, Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Cara Therapeutics?
Cara Therapeutics was acquired by Tvardi Therapeutics, Inc., based in Houston. The deal was reported on April 21, 2025. Tvardi Therapeutics, Inc. is privately held and operates in Healthcare.
When did Tvardi Therapeutics, Inc. acquire Cara Therapeutics?
Tvardi Therapeutics, Inc.'s acquisition of Cara Therapeutics was reported on April 21, 2025. Tvardi Therapeutics has completed its merger with Cara Therapeutics, creating a Nasdaq-listed company focused on STAT3 therapies for fibrosis-driven diseases. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Cara Therapeutics do?
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. It is privately held, operating in Biotechnology, and is based in Stamford.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.